MetaStat, Inc. is developing next-generation diagnostic and therapeutic products for metastatic cancer, which is the cause of up to 90% of solid tumor cancer-related deaths. The Company’s pipeline is based on over 15 years of research and collaboration by the Massachusetts Institute of Technology (MIT), Albert Einstein College of Medicine of Yeshiva University, Cornell University, and Italy’s IFO-Regina Elena Cancer Institute.
MetaStat’s platform technologies may improve diagnosis and treatment for up to 80% of all solid tumor cancers, including breast, prostate, lung, bowel, pancreatic, brain, liver, and head and neck cancers.
MetaStat’s technology focuses on predicting the risk of cancer metastasis based on its underlying mechanisms, which entails identifying the structural and behavioral mechanisms that allow cancer cells to move and determining how this information can be used in prognosis. To MetaStat’s knowledge, its technology is the only technique to focus on such mechanistic markers.
MetaStat’s initial product opportunity is MetaSite Breast, a candidate designed to predict the risk of breast cancer progression. MetaSite Breast has been validated in clinical studies and the Company expects it to have a low-cost and rapid path to market as early as 2015.
MetaStat’s products are designed to overcome limitations of gene-based diagnostic tests in order to improve the quality of treatment decisions. Clinical data suggests that MetaSite Breast enables a higher degree of precision in stratifying risk than competitive products.
Breast cancer is one of the most commonly diagnosed cancers for women. In 2013, more than 232,000 women were thought to have been diagnosed with invasive breast cancer in the U.S., adding to the millions of women already living with this diagnosis (Source: Breast Cancer Facts & Figures 2013).
The Company is also developing multiple products based on its MenaCalc diagnostic platform: (1) MenaCalc Breast; (2) MenaCalc Lung; (3) MenaCalc Prostate; and (4) MenaCalc Colorectal.
A correlation between the MenaCalc Breast Metastasis Score and the MetaSite Breast Metastasis Score has been confirmed in a 797-patient study. In addition, the Company believes its MenaCalc Breast test can provide diagnostic and prognostic information for women with all sub-types of breast cancer, which has the potential to separate MetaStat from the competition.
Unpublished data collected in lung adenocarcinoma and prostate tumors have shown the ability of MenaCalc to predict cancer spread in these cancer types.
In October 2013, MetaStat opened a drug discovery laboratory in affiliation with Stony Brook University in order to advance its MenaBloc program for identifying potential therapeutic targets for metastatic cancer. The Company has recruited well-known cancer researchers from OSI Pharmaceuticals to head up its drug discovery efforts.
MetaStat holds rights to three issued U.S. patents and 10 pending patent applications globally.
MetaStat’s leadership is experienced in biotechnology/life sciences research and management, including at major global firms such as Roche. The Company possesses highly skilled Scientific and Clinical Advisory Boards, with individuals from MIT, the Albert Einstein College of Medicine, and Cornell who were instrumental in pioneering the academic research supporting MetaStat’s product development.
As of November 30, 2013, MetaStat had $488,108 in cash. The Company seeks to raise $5 million to $7 million to reach important milestones.